MNPR
Monopar TherapeuticsBS score 46.4MEDIUMPHASE3 · mkt cap $387.6M · rev ttm $0
drug hypothesis
MNPR-101-PCTA-177Lu modulates Not explicitly stated in provided data; PCTA typically refers to Prostate Cancer Target Agent (likely PSMA), but this is not confirmed to treat Multiple solid tumors: bladder cancer, urothelial carcinoma, triple-negative breast cancer, lung cancer, colorectal cancer, gastric cancer, ovarian cancer, pancreatic cancer.
moa:Not provided in available data
score breakdown
trial design70
base rate disconnect6
language red flags80
composite46.4
valuation analysis
market cap$387.6M
revenue ttm$0
phasePHASE3
historical base rate35%
disconnect ratio0.2x
lead trialNCT06980506
meta
cik0001645469
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1 dose-escalation study, non-randomized, open-label, not placebo-controlled, enrolling 12 adult patients with solid tumors
primary endpoint:Identify dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency over 6 weeks after first dose
claimed differentiation
Not provided in available data
language red flags
- Target not explicitly stated - requires assumption based on 'PCTA' abbreviation
- Insufficient data provided to assess differentiation claims
- No preclinical evidence or business section text included in filing
- No stated risks or catalysts identified in available data